Crescendo woos GSK dealmaker
Crescendo Biologics, the Cambridge drug developer of novel, targeted T cell enhancing therapeutics, has appointed ex-GSK deal supremo Stewart Kay as chief business officer.
Kay has more than 20 years’ experience in business development in both biotech and big pharma. Most recently he was senior director, Transactions, at GlaxoSmithKline in the Worldwide Business Development group.
During his time at GSK, he was the lead negotiator on a wide variety of deals across multiple therapeutic areas including oncology, immuno-inflammation, respiratory and rare diseases.
He was responsible for a range of early and late stage clinical in-and out-licensing agreements and numerous transactions relating to pre-clinical assets and technology platforms.
Before joining GSK, Kay also held senior roles in business development and marketing at Asterand plc, Evotec AG and Amersham Biosciences (now GE Healthcare).
Theodora Harold, CEO of Crescendo Biologics, said: “Stewart has an impressive track record of leading negotiations across a broad range of transactions in the biotech and pharmaceutical sectors.
“With our lead programme for PSMA positive tumours entering phase I soon, and a number of innovative, first-in-class, T cell enhancing programmes following behind, 2020 will be an important year for us. Stewart’s extensive experience will be indispensable to us as we drive Crescendo forward.”
Kay added: “Crescendo has made great progress over the past few years and has established itself as a key player in the CD137 space with the acceleration of its lead programme, CB307, towards the clinic.
“I am impressed by the progress made in the collaboration with Takeda and am looking forward to working with the rest of the team to realise the potential of Humabody® therapeutics.”